Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
German finance minister sees advantages of smartphones in schools - 2Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
- 35 Cell phones of the Year
- 4Agricultural drones are taking off globally, saving farmers time and money
- 5Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 4 injured in shooting at North Carolina tree lighting ceremony
- What Yogurt Types Do You Know
- Language Learning Stages: Which One Gets Your Vote?
- Vote In favor of Your Favored IT Administration
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Foreign military officials can become Israel's ambassadors, senior IDF commander tells 'Post'
- Manual for Tracking down the Nearby Business sectors and Marketplaces
- Understanding the Rudiments of Tree Administrations
- Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
